Baxter buys Baxa for $380M; FDA says no to migraine patch;

> Baxter International ($BAX) has agreed to pay $380 million for Baxa, which develops pharmacy technology for oral and IV dose preparation and delivery. The deal is designed to enhance Baxter's nutrition and drug-delivery business. Item | Release

> FDA says no to NuPathe's Zelrix migraine patch. Article

> Drug-eluting balloons in long infrapopliteal arteries could be safe and effective, but more clinical trials are necessary to prove their worth. Story

> Drug delivery patent application of the week: Modified polysaccarides for drug and contrast agent delivery. Patent application

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.